Emergent BioSolutions (EBS) News
NYSE: EBSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
5.05-0.10 (-1.94%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EBS news summary
We found 4 recent headlines mentioning Emergent BioSolutions (EBS): 0 in the past week and 3 in the past 30 days, most often from Nasdaq, Business Wire. For price context, EBS is down 1.94% at $5.05. The most recent story, "Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors", was published by Nasdaq on Nov 3, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Emergent BioSolutions headlines
- Emergent BioSolutions: 3 Key Takeaways for Long-Term InvestorsKey PointsFull-year revenue guidance was updated to $600 million to $645 million.Nasdaq
- Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Emergent Biosolutions Reports Third Quarter 2026 Financial ResultsGAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2026. “Emergent's third-quarter results, which…Business Wire
- Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, November 2, 2026, at 5:00 p.m. eastern time to discuss the financial results for the…Business Wire